

# VÃ¢nia M Morelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10107302/publications.pdf>

Version: 2024-02-01

35  
papers

481  
citations

840776

11  
h-index

713466

21  
g-index

35  
all docs

35  
docs citations

35  
times ranked

697  
citing authors

#	ARTICLE	IF	CITATIONS
1	ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. <i>Thrombosis and Haemostasis</i> , 2007, 97, 534-541.	3.4	73
2	The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6 -174GC, IL-8 -251AT and MCP-1 -2518AG in the risk of venous thromboembolism: A case-control study. <i>Thrombosis Research</i> , 2011, 128, 216-220.	1.7	69
3	Lipid levels and risk of venous thrombosis: results from the MEGA-study. <i>European Journal of Epidemiology</i> , 2017, 32, 669-681.	5.7	35
4	Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism. <i>Blood Advances</i> , 2021, 5, 224-232.	5.2	32
5	Role of microRNAs in Venous Thromboembolism. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2602.	4.1	28
6	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 297-303.	3.8	27
7	Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1618-1626.	3.8	27
8	ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. <i>Thrombosis and Haemostasis</i> , 2007, 97, 534-41.	3.4	26
9	Cytokine gene variants and venous thrombotic risk in the BRATROS (BRAZILIAN THROMBOSIS STUDY). <i>Thrombosis Research</i> , 2007, 120, 221-229.	1.7	13
10	Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism. <i>Blood</i> , 2021, 138, 2269-2277.	1.4	13
11	Polymorphisms in antithrombin and in tissue factor pathway inhibitor genes are associated with recurrent pregnancy loss. <i>Thrombosis and Haemostasis</i> , 2012, 108, 693-700.	3.4	12
12	Risk factors associated with recurrent venous thromboembolism after a first cerebral venous thrombosis event: A cohort study. <i>Thrombosis Research</i> , 2019, 178, 85-90.	1.7	12
13	Glucose levels and diabetes are not associated with the risk of venous thrombosis: results from the MEGA case-control study. <i>British Journal of Haematology</i> , 2019, 184, 431-435.	2.5	11
14	Plasma levels of growth differentiation factor 15 are associated with future risk of venous thromboembolism. <i>Blood</i> , 2020, 136, 1863-1870.	1.4	11
15	Haplotypes of TAFI gene and the risk of cerebral venous thrombosis - a case-control study. <i>Thrombosis Research</i> , 2014, 133, 120-124.	1.7	10
16	Risk factors and predictors for venous thromboembolism in people with ischemic stroke: A systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2173-2186.	3.8	10
17	A transcobalamin gene polymorphism and the risk of venous thrombosis. The BRATROS (Brazilian) Tj ETQq1 1 0.784314 rgBT <sub>9</sub> /Overlook	1.7	9
18	Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism. <i>Thrombosis Research</i> , 2021, 208, 121-126.	1.7	9

#	ARTICLE	IF	CITATIONS
19	Effect of prothrombotic genotypes on the risk of venous thromboembolism in patients with and without ischemic stroke. The TromsÅ, Study. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 749-758.	3.8	8
20	Myocardial infarction, prothrombotic genotypes, and venous thrombosis risk: The TromsÅ, Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 247-254.	2.3	7
21	D-Dimer Measured at Diagnosis of Venous Thromboembolism is Associated with Risk of Major Bleeding. <i>TH Open</i> , 2019, 03, e77-e84.	1.4	6
22	Myocardial Infarction as a Transient Risk Factor for Incident Venous Thromboembolism: Results from a Population-Based Caseâ€Crossover Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1358-1364.	3.4	5
23	Impact of prothrombotic genotypes on the association between family history of myocardial infarction and venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1363-1371.	3.8	5
24	Plasma Levels of Leptin and Risk of Future Incident Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2022, 122, 560-569.	3.4	5
25	Platelet count and risk of major bleeding in venous thromboembolism. <i>Platelets</i> , 2021, 32, 444-452.	2.3	4
26	Joint Effect of Multiple Prothrombotic Genotypes and Obesity on the Risk of Incident Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2022, 122, 267-276.	3.4	4
27	Chronic Obstructive Pulmonary Disease and Risk of Mortality in Patients with Venous Thromboembolismâ€The TromsÅ, Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 477-483.	3.4	3
28	Association Between Hepatic Triglyceride Content and Coagulation Factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 3004-3014.	2.4	3
29	Joint effect of myocardial infarction and obesity on the risk of venous thromboembolism: The TromsÅ, Study. <i>Journal of Thrombosis and Haemostasis</i> , 0, , .	3.8	2
30	Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1. <i>Leukemia and Lymphoma</i> , 2014, 55, 1176-1180.	1.3	1
31	Prothrombotic genotypes and risk of major bleeding in patients with incident venous thromboembolism. <i>Thrombosis Research</i> , 2020, 191, 82-89.	1.7	1
32	Role of Routine Laboratory Tests in Assessing Risk of Recurrent Venous Thrombosis: Results from the MEGA Follow-Up Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1918-1929.	3.4	0
33	Comparison of aPTT (Platelin LSÂ®) and Dilute Russellâ€™s Viper Venom (Viperquik LA TestÂ®) for the Screening of Lupus Anticoagulant in Patients with Venous Thromboembolism.. <i>Blood</i> , 2005, 106, 4122-4122.	1.4	0
34	Procoagulant Activity in Sickle Cell Anemia.. <i>Blood</i> , 2007, 110, 3789-3789.	1.4	0
35	Inflammatory Cytokines: TNF±, IL-1Î², IL-6 and IL-8 in Pulmonary Hypertension of Sickle Cell Disease.. <i>Blood</i> , 2007, 110, 3787-3787.	1.4	0